Core Insights - Altimmune, Inc. has appointed Dr. Christophe Arbet-Engels as Chief Medical Officer to lead the Phase 3 development of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) [1][2] - Dr. Arbet-Engels brings over 30 years of experience in clinical development, regulatory approvals, and commercial launches, which will be crucial for advancing pemvidutide [2] - The company aims to establish a new standard of care in treating hepato-metabolic disorders, with upcoming data from the IMPACT trial and ongoing Phase 2 trials in Alcohol Use Disorder and Alcohol-associated Liver Disease [2] Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases [6] - The lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist targeting MASH, Alcohol Use Disorder, Alcohol-associated Liver Disease, and obesity [6] Leadership Transition - Dr. Scott Harris, the previous Chief Medical Officer, will retire but remain as a Senior Strategic Advisor until February 2026 [1][2] - Dr. Arbet-Engels has previously held senior roles at X4 Pharmaceuticals, Neurogastrx, Millendo Therapeutics, and Poxel Pharmaceuticals, contributing to successful regulatory processes and clinical programs [2] Inducement Grant Details - Dr. Arbet-Engels will receive options to purchase 450,000 shares and 150,000 restricted stock units (RSUs) as part of his compensation package [3][4] - The options will vest over four years, with one-fourth vesting on the one-year anniversary of the grant date [4][5] - The RSUs will also vest over four years, with one-fourth vesting on the one-year anniversary and the remainder in three equal installments [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, of the October 6, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To participate in the class action, investors must move the Court by October 6, 2025, to serve as lead plaintiff, representing other class members [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Background - The lawsuit alleges that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, failing to meet a key statistical significance marker for fibrosis reduction [4] - Altimmune is accused of inflating expectations for positive results while concealing adverse data from the placebo group, leading to investor damages when the true results were revealed [4]

Core Viewpoint - Berger Montague PC is investigating claims against Altimmune, Inc. following a class action lawsuit related to the company's performance and disclosures regarding its clinical trials [1][3]. Group 1: Company Overview - Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) [1]. Group 2: Legal Actions - A class action lawsuit has been filed against Altimmune, with investors who purchased securities between August 10, 2023, and June 25, 2025, having until October 6, 2025, to seek appointment as lead plaintiff [2]. - The lawsuit follows the announcement of topline results from Altimmune's IMPACT Phase 2b trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint [3][4]. Group 3: Financial Impact - Following the announcement of the trial results, Altimmune's stock price dropped from $7.71 on June 25, 2025, to $3.61 on June 26, representing a decline of over 53% in one day [4].

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 10, 2023, and June 25, 2025 [1][2] Case Details - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [2] - The stock price of Altimmune dropped from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [2] Next Steps - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4]

Core Viewpoint - Altimmune, Inc. (NASDAQ: ALT) faces a class action lawsuit following the announcement of disappointing results from its IMPACT Phase 2b MASH trial, leading to a significant drop in stock price [1]. Group 1: Company Performance - On June 26, 2025, Altimmune reported topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [1]. - The stock price of Altimmune plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in just one day [1]. Group 2: Legal Proceedings - Shareholders who purchased shares of ALT between August 10, 2023, and June 25, 2025, are encouraged to register for the class action lawsuit, with a deadline for lead plaintiff appointment set for October 6, 2025 [2]. - The Gross Law Firm is leading the class action, aiming to protect investors who suffered losses due to misleading statements from the company [3].

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its Phase 2b MASH trial, leading to significant stock price decline [8]. Allegation Details - The lawsuit claims that Altimmune provided inflated expectations prior to the announcement of the trial results on June 26, 2025, which revealed a failure to achieve statistical significance in the primary endpoint of fibrosis reduction [8]. - The stock price of Altimmune dropped from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [8]. Next Steps - Investors who purchased Altimmune shares between August 10, 2023, and June 25, 2025, and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, about the lead plaintiff deadline of October 6, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors can join the action without any out-of-pocket fees through a contingency fee arrangement [1][2]. - Investors wishing to serve as lead plaintiff must file with the Court by October 6, 2025, to represent other class members in the litigation [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Background - The lawsuit alleges that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, claiming they had reliable information while failing to meet a key statistical significance marker for fibrosis reduction [4]. - The company is accused of inflating expectations for positive results while concealing adverse data from the placebo group, which negatively impacted the trial's topline results [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after disappointing trial results for Pemvidutide, with a reminder of the upcoming deadline for investors to seek lead plaintiff status in a federal securities class action [2][3][4]. Group 1: Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction, despite prior inflated expectations [3]. - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a dramatic decline of 53.2% in just one day [4]. Group 2: Legal Actions - Investors who suffered losses exceeding $75,000 in Altimmune between August 10, 2023, and June 25, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The firm is reminding investors of the October 6, 2025, deadline to seek the role of lead plaintiff in the class action lawsuit against Altimmune [2][5].

GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Stifel 2025 Virtual Cardiometabolic ForumTuesday, September 30, 2025Fireside Chat at 10:30 a.m. Eastern Time H.C. Wainwright Liver Disease Virt ...

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 10, 2023, and June 25, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2]. - The company's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a significant decline of 53.2% in just one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].